Drug intelligence / Profile preview

serdexmethylphenidate

Development stage
Phase 4
Lead developer
Zevra Therapeutics
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Oral
01

Overview

Serdexmethylphenidate is a prodrug of the central nervous system (CNS) stimulant dexmethylphenidate. It is used in combination with dexmethylphenidate for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged six years and older. The drug increases extracellular levels of dopamine and norepinephrine in the CNS by blocking their reuptake into presynaptic neurons, leading to altered neurotransmission. Serdexmethylphenidate itself has little or no binding to monoaminergic reuptake transporters; its therapeutic effect is due to its conversion to active dexmethylphenidate[3][5][6]. The combination product provides extended plasma concentrations and therapeutic benefit with once-daily dosing[6].

Brand names
Azstarys
Other names
KP-415 inner saltKP415 inner saltKP 415 inner saltUNII-0H8KZ470DWUNII0H8KZ470DWUNII 0H8KZ470DW1996626-29-9
02

Targets

NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on serdexmethylphenidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on serdexmethylphenidate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call